In addition, different clinical studies have convincingly shown that the amount of both CD36 mRNA and protein was higher in the livers of biopsy-proven NAFLD patients than in subjects with histologically normal liver (12–14). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.